Low base supported overall performance; consolidated sales from operations came in at Rs 8,431 crore, up 4.4% YoY
Nifty holds 15,300, sees all-time closing high, RBI flags risk of bubble in Indian equity markets and other top news of the day
Its revenue from operations came in at Rs 8,522 crore for the quarter under review, an increase of 4 per cent from the previous year
BPCL's board has approved a final dividend of Rs 58 per share, which includes a one-time special dividend of Rs 35 per equity share
Drug major Sun Pharma is recalling 50,868 bottles of diabetes drug Metformin HCl extended-release tablets in the US market, according to the US Food and Drug Administration (USFDA).
Since April, the index has outperformed the market by surging 15 per cent, against 1.7 per cent gain in the Nifty50; Sun Pharma scales 4-year high
Since April, the Nifty Pharma index has outperformed the market by surging 15 per cent, against 1.7 per cent gain in the Nifty50 index
Analysts at Phillip Capital believe that it is not over for the Indian pharma - and that it is all set for a sectoral value upgrade
Union minister Nitin Gadkari has called up Sun Pharma's chief to arrange for 10,000 injections of Remdesivir in Nagpur in view of a shortage of the medicine here in Maharashtra
Strong US portfolio, margin gains and India business growth to support stock
The recent price chart displays a 'Bullish Flag' breakout in Happiest Minds' stock
IndusInd Bank, Kotak Mahindra Bank, ICICI Bank, Sun Pharma, Bajaj Finance, and UltraTech Cement were prominent gainers
Sun Pharma, Dr Reddy's Laboratories, Aurobindo Pharma and Jubilant Pharma are recalling products in the US market, the world's largest market for pharmaceutical products, for various reasons
Key chronic segments have helped the JB Chemicals outperform the Indian pharma market.
The firm said it plans to introduce a complete range of anti-epilepsy drug Brivaracetam in the country at an affordable price
Markets regulator Sebi on Thursday allowed Thomas Cook (India) to withdraw its buyback offer because of substantial deterioration in the company's financial position
The stock price has witnessed running correction of 10 per cent from the recent high
Two whistle blowers had alleged that Sun Pharma and its subsidiary Sun Pharmaceutical Laboratories diverted funds through its sole distributor in India Aditya Medisales
Respiratory segment and anti-infectives contract; Cardiac, anti-diabetic growth rates plummet
At 12:57 pm, Nifty Pharma index, the top gainer among sectoral indices, was up 4.2 per cent, as compared to 1.3 per cent gain in the benchmark Nifty50 index